The largest database of trusted experimental protocols

27 protocols using rat igg2a

1

Adalimumab Modulates CD4+ T-Cell Interactions with RA Fibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bulk CD4+ T cells were cultured and stimulated as described above for 7 days in the absence or presence of adalimumab (1 µg/mL), with supplementation of 20 U/mL (Peprotech) of IL‐2 on day 4. Cells were washed and rested for 24 h at 37°C. Fibroblasts generated from RA patients' knee replacement synovial tissue were seeded in 96‐well flat bottom plates at a density of 10 000/well in DMEM, supplemented with 10% FCS, 1% penicillin/streptomycin, 2% l‐glutamine (all from GIBCO), and 1 µg/mL Amphotericin B/Fungizone (GIBCO) and allowed to adhere for 24 h. Twenty‐five thousand pre‐cultured CD4+ T cells were added to the fibroblasts and cultured in DMEM for 3 days with soluble aCD3 mAb (100 ng/mL) with or without 10 µg/mL of anti‐IL‐10 (JES3‐19F1, Rat IgG2a, Biolegend) and anti‐IL‐10R (3F9, Rat IgG2a, Biolegend) blocking antibodies or matching isotype control Ab (RTK2758, Rat IgG2a, Biolegend). Supernatants were collected post co‐culture.
+ Open protocol
+ Expand
2

Phenotyping Murine Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The monoclonal anti-mouse antibodies used were: Anti-CD3-PE (17A2), Anti-CD3-PerCP/Cy5.5 (17A2), Anti-Ly6G-PE/Cy7 (1A8), Anti-Ly6G-APC/Cy7 (1A8), Anti-CD11b-APC (M1/70), Anti-Ly6C-AF700 (HK1.4), Anti-CD8-APC/Cy7 (53–6.7), Anti-F4/80-APC-Cy7 (BM8) (Biolegend, CA, USA); Anti-CD4-FITC (GK1.5), Anti-CD45-FITC (30-F115), Anti-CD45-PerCP/Cy5.5 (30-F11), Anti-CD11b-eF450 (M1/70) (eBioscience, Thermo Fisher Scientific, MA, USA). The following Isotype control was used: rat IgG2a, κ isotype control-APC-Cy7 (RTK2758, Biolegend). Dead cells were excluded by a live/dead fixable aqua dead cell stain kit (Invitrogen Thermo Fisher Scientific, MA, USA). Cell acquisition and analysis were performed using Gallios Flow Cytometer (Beckman Coulter, Nyon, Switzerland) and FlowJo software (Tree Star, Ashland, OR), respectively.
+ Open protocol
+ Expand
3

Investigating CD49e Antibody Treatment in EAE Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
EAE mice (n = 10 per group) were treated daily with 200 ug of CD49e (α5 integrin) antibody (Clone= 5H10–27(MFR5)) or rat IgG2a, kappa isotype control (low endotoxin, azide-Free antibody, custom-made by Biolegend for this experiment). Treatment with antibody and isotype was initiated once immunized mice developed paralysis (representing clinical EAE) on day15.
EAE scores were assessed daily for clinical signs of EAE in a blinded fashion without knowing which mouse was receiving treatments. Mice were assessed daily and scored according to: 0, no clinical disease; 1, tail weakness; 2, hindlimb weakness; 3, complete hindlimb paralysis; 4, hindlimb paralysis and some forelimb weakness; 5, moribund or dead. The experiment was concluded due to high morbidity of control mice.
+ Open protocol
+ Expand
4

Immunohistochemical Analysis of GP2 and Peyer's Patches in Intestinal Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols
Pancreas, Peyer’s patches, large intestine, gastrointestinal ducts (stomach, small intestine, and large intestine) including luminal contents, submandibular glands and sublingual glands were fixed in 4% paraformaldehyde (Wako) and embedded in paraffin or followed by 15% sucrose cryoprotection at 4 °C overnight and embedded in OCT compound (Sakura Finetek Japan). Large intestine without luminal content was fixed in 4% paraformaldehyde and embedded in paraffin. After embedding, 5-μm sections were cut and stained with the following antibodies: for GP2 detection, anti-mGP2 (MBL, 2F11-C3, #D278-3, 1:200) and Alexa 555-conjugated anti-rat IgG (BioLegend, Poly4054, #405420, 1:200). To confirm that GP2 signal was correct, serial sections were stained with isotype control (rat IgG2a, BioLegend, RTK2758, #400501, 1:100) and Alexa 555-conjugated anti-rat IgG in all samples; for Peyer’s patch FAE, fluorescein isothiocyanate (FITC)-conjugated UEA-1 (Vector Laboratories, # FL-1061, 1:100). DAPI (4′,6-diamidino-2-phenylindole; Dojindo, #D523, 1:1000) was used for counter staining. Observations were performed under a fluorescence microscope (BZ-9000; Keyence). Hematoxylin (Wako) and eosin (Wako) staining was performed by using standard procedures.
+ Open protocol
+ Expand
5

Transwell Assay for Cell Migration

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell migration assays were performed using Transwell chambers (pore size 5 μm, Costar, Corning 3421, Corning, NY, USA). THP-1 cells (2 × 106 in 200 μl) were re-suspended in serum-free RPMI 1640 medium and added to the upper chamber. Supernatant from infected 786-O cells was mixed with 1 μg/ml neutralizing antibody against human GM-CSF (502203, BVD2-23B6, Biolegend) or control IgG2a (400515, Rat IgG2a, Biolegend) and incubated for 30 min. Then, 600 μl of medium containing the supernatant was added to the lower chamber as the chemoattractant. After 3 h or 6 h of incubation at 37 °C in a 5% CO2 humidified atmosphere, the migrated cells in the lower chamber were counted.
+ Open protocol
+ Expand
6

Monoclonal Anti-Mouse IL-1α Antibody in TBI

Check if the same lab product or an alternative is used in the 5 most similar protocols
The mice were injected i.p. with 4 µg per mouse a monoclonal anti-mouse IL-1α antibody (Ab) (BioLegend, Germany) or isotype control Ab (rat IgG2a, BioLegend, Germany) in 100 µl of NS 24 h before TBI (total body irradiation) and 24 h after BMT.
+ Open protocol
+ Expand
7

PD-L1 and PD-L2 Expression Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were stained for PE-conjugated anti-human PD-L2 (Cat#329606, Biolegend) or APC-conjugated anti-human PD-L1 antibody (Cat#329708, Biolegend) at 1:100 dilution on ice for 30 mins and analyzed by BD FACSCalibur. Isotype controls are mouse IgG2a, κ (Cat#400213, Biolegend) and mouse IgG2b, κ (Cat#400322, Biolegend), respectively. GL261 cells overexpressing PD-L1 and/or PD-L2 were stained for PE-conjugated anti-mouse PD-L2 (Cat#107205, Biolegend) and/or APC-conjugated anti-mouse PD-L1 antibody (Cat#124312, Biolegend) at 1:100 dilution on ice for 30 minutes and sorted using a BD FACSAria III cell sorter. Isotype controls were Rat IgG2a, κ (Cat#400508, Biolegend) and Rat IgG2b, κ (Cat#400612, Biolegend), respectively.
+ Open protocol
+ Expand
8

Comprehensive Flow Cytometry Antibody Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antibodies for flow cytometry experiments: anti-mouse CD3; anti-mouse CD4; anti-mouse CD8a; anti-mouse CD25; anti-mouse CD38; anti-mouse CD69; anti-mouse CD70; anti-mouse CD11b; anti-mouse CD11c; anti-mouse CD19; anti-CD62L; anti-mouse CD80; anti-mouse CD86; anti-mouse CD68; anti-mouse F4/80; anti-mouse TNFα; anti-Granzyme B; anti-mouse/human CD44; anti-mouse CD183 (CXCR3); anti-mouse CD184 (CXCR4); anti-mouse CD185 (CXCR5); anti-mouse CD186 (CXCR6); anti-mouse CD1d; anti-mouse CD120a (TNFRSF1a); anti-mouse CD152 (CTLA-4); anti-mouse CD279 (PD-1); anti-mouse CD274 (B7-H1 or PD-L1); anti-mouse CD273 (B7-DC or PD-L2); anti-mouse CD117 (c-Kit); anti-mouse Ly-6A/E (SCA-1); anti-mouse Lineage Cocktail with Isotype Ctrl; mouse IgG1, κ Isotype; mouse IgG2b, κ Isotype Ctrl; mouse IgG2a, κ Isotype; rat IgG2b, κ Isotype; Armenian Hamster IgG Isotype; Syrian Hamster IgG Isotype; rat IgG2a, κ Isotype and rat IgG1, κ Isotype Ctrl were procured from BioLegend. The anti-mouse CD34, anti-perforin 1 antibodies and regulatory T cells (Treg) staining kit were purchased from eBioscience.
+ Open protocol
+ Expand
9

ICOS Blockade and ILC Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
For ICOS blockade experiments, an anti-ICOSL antibody (#107410; BioLegend; 20 µg/20 µl in Sal) was delivered intranasally for three consecutive days 3 d before analysis in week 8. An isotype rat IgG2a (#400544; BioLegend) antibody was used as a control. For NK1.1 and ILCs cell depletion, we used as anti-NK1.1(#BE0036, clone PK136; Bio X Cell) and anti-CD90.2 (#BE0066, clone 30H12; Bio X Cell), respectively. Mouse IgG2a (#BE0085, clone C1.18.4; Bio X Cell) and rat IgG2b (#BE0090, clone LTF-2; Bio X Cell) antibodies were used as isotype controls, respectively. For ILC2 depletion in vivo, we treated mice with SR3335 (200 µg/dose, i.p.) or vehicle (ethanol diluted with Sal; final ethanol concentration 20 µl/dose) on two consecutive days before the recall challenge.
+ Open protocol
+ Expand
10

Canine CD20 Antibody Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Each cell was collected and washed with flow cytometry buffer (PBS with 2% FBS and 0.1% NaN3). 2 × 105 cells were stained with the primary antibody: an anti-canine CD20 antibody (4E1-7, 4E1-7-B, 4E1-7-C, or 1E-4-B), a PE-labeled anti-CD21 antibody (Bio-Rad Laboratories, Inc., Berkeley, CA), or an isotype control (rat IgG2a, BioLegend, San Diego, CA, USA), followed by a secondary antibody: PE-labeled anti-rat IgG (SouthernBiotech, Birmingham, AL), Dylight 649-labeled anti-rat IgG (BioLegend), or Alexa 647-labeled anti-dog IgG (Jackson ImmunoResearch, West Grove, PA, USA).
To determine the subclass of 4E1-7, NRK/cCD20 cells were first stained with the anti-canine CD20 antibody (4E1-7), and then stained with either biotin-labeled anti-rat IgG-κ, anti-rat IgG-λ, anti-rat IgG1, anti-rat IgG2a, or anti-rat IgG2b antibody, followed by incubation with streptavidin-PE (Thermo Fisher Scientific Inc.). Results obtained using a BD Accuri C5 flow cytometer (BD Biosciences) were analyzed using FlowJo v.10 software (Tree Star Inc., Ashland, OR, USA).
Binding affinity of each antibody was determined by flow cytometry. Each cell was stained by the serially diluted antibody, as described above. Kd value was determined using the Nonlinear Regression Michaelis–Menten curve fit by JMP14.0 software (JMP Japan, Tokyo, Japan).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!